Physician profile
David Kim
NPI 1558568634
$5,851.49
in general payments reported to CMS, 2019-2025
30 companies · $765 in 2025
The $765 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $736 · 2020: $382 · 2021: $966 · 2022: $884 · 2023: $1,090 · 2024: $1,028 · 2025: $765.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,884.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,883.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,093.26 | 2019-2025 | Rocklatan, Clareon, Argos |
| Abbvie INC. | $890.26 | 2022-2025 | |
| Genentech USA, INC. | $668.78 | 2019-2025 | Vabysmo |
| Regeneron Healthcare Solutions, INC. | $583.34 | 2019-2025 | Eylea Hd, Eylea |
| Biotissue Holdings INC. | $367.89 | 2019-2024 | |
| Sight Sciences, INC. | $222.61 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Novartis Pharmaceuticals Corporation | $199.47 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $185.74 | 2021-2023 | Acthar |
| Aerie Pharmaceuticals, INC. | $184.80 | 2020-2021 | |
| Oyster Point Pharma, INC. | $177.60 | 2022-2024 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $169.98 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $160.32 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $155.97 | 2019-2023 | Cequa |
| Thea Pharma INC. | $129.46 | 2023-2025 | Iyuzeh |
| Allergan, INC. | $88.49 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $79.15 | 2024 | Iheezo, Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $61.76 | 2019-2020 | |
| Glaukos Corporation | $50.46 | 2025 | Photrexa Viscous and Photrexa |
| Kala Pharmaceuticals, INC. | $50.17 | 2020-2021 | |
| Biogen, INC. | $50.02 | 2022-2024 | Byooviz |
| Rxsight INC | $49.97 | 2023-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Apellis Pharmaceuticals, INC. | $45.94 | 2023-2024 | Syfovre |
| Carl Zeiss Meditec, INC. | $44.34 | 2020 | |
| Rayner Intraocular Lenses Limited | $30.64 | 2025 | Omidria |
| Optos, INC. | $25.00 | 2021 | |
| Coopervision INC. | $22.26 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Johnson & Johnson Surgical Vision, INC. | $18.00 | 2023 | Tecnis Iol, Tecnis Iol |
| Bausch & Lomb Americas INC. | $14.41 | 2025 | Miebo, Xiidra |
| Boston Scientific Corporation | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.